Annidis Corp. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
1,144.50
1,066.80
2,364.00
1,898.70
1,143.30
Cost of Goods Sold (COGS) incl. D&A
1,254.90
1,355.20
2,524.50
1,927.80
1,504.80
Gross Income
110.50
288.40
160.40
29.20
361.50
SG&A Expense
3,437.50
3,366.30
4,711.10
4,558.00
3,085.30
EBIT
3,548.00
3,654.70
4,871.50
4,587.20
3,446.80
Non Operating Income/Expense
590.20
131.60
118.40
-
-
Interest Expense
438.80
785.60
919.60
1,368.40
1,457.40
Pretax Income
4,577.00
4,308.60
5,672.80
5,955.50
4,904.20
Income Tax
33.00
-
-
-
-
Consolidated Net Income
4,544.00
4,308.60
5,672.80
5,955.50
4,904.20
Net Income
4,544.00
4,308.60
5,672.80
5,955.50
4,904.20
Net Income After Extraordinaries
4,544.00
4,308.60
5,672.80
5,955.50
4,904.20
Net Income Available to Common
4,544.00
4,308.60
5,672.80
5,955.50
4,904.20
EPS (Basic)
0.07
0.06
0.06
0.06
0.05
Basic Shares Outstanding
66,344.50
72,924.70
88,735.20
95,517.20
108,240.40
EPS (Diluted)
0.07
0.06
0.06
0.06
0.05
Diluted Shares Outstanding
66,344.50
72,924.70
88,735.20
95,517.20
108,240.40
EBITDA
3,293.90
3,434.40
4,578.90
4,331.40
3,272.60

About Annidis

View Profile
Address
100 Maple Grove Road
Ottawa Ontario K2V 1B8
Canada
Employees -
Website http://www.annidis.com
Updated 07/08/2019
Annidis Corp. is a holding company, which engages in the research and development of eye care equipment. It provides eye-centric products and services that helps eye care professionals screen, detect, diagnose, treat and manage ocular diseases. Its RHA is an ocular pathology management system that integrates advanced multi-spectral imaging and analytic software for early detection and management of ocular pathologies, such as glaucoma, age related macular degeneration and diabetic retinopathy.